Monast Dosage/Direction for Use

Montelukast should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs.
Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.
FC tablet: Adults 15 Years of Age and Older with Asthma and/or Seasonal Allergic Rhinitis: The dosage for adults 15 years of age and older is one 10-mg tablet daily.
Chewable tablet: Pediatric Patients 2 to 5 Years of Age with Asthma and/or Seasonal Allergic Rhinitis: The dosage for pediatric patients 2 to 5 years of age is one 4-mg chewable tablet daily.
Pediatric Patients 6 to 14 Years of Age with Asthma and/or Seasonal Allergic Rhinitis: The dosage for pediatric patients 6 to 14 years of age is one 5-mg chewable tablet daily.
General Recommendations: The therapeutic effect of montelukast on parameters of asthma control occurs within one day. Montelukast tablets and chewable tablets can be taken with or without food. Patients should be advised to continue taking Montelukast while their asthma is controlled, as well as during periods of worsening asthma.
No dosage adjustment is necessary for elderly, pediatric patients, for patients with renal insufficiency, or mild-to-moderate hepatic impairment, or for patients of either gender.
Montelukast is a long term-controller medication which should not be substituted for short acting beta-agonists. It is effective alone or in combination with other prophylactic agent.
Montelukast is a preventive agent, which should be used in addition to other drugs for the management of asthma.
Therapy with Montelukast in Relation to Other Treatments for Asthma: Montelukast can be added to a patient's existing treatment regimen.
Reduction in Concomitant Therapy: Bronchodilator Treatments: Montelukast can be added to the treatment regimen of patients who are not adequately controlled on bronchodilator alone. When a clinical response is evident (usually after the first dose), the patient's bronchodilator therapy can be reduced as tolerated.
Inhaled Corticosteroids: Treatment with Montelukast provides additional clinical benefit to patients treated with inhaled corticosteroids. A reduction in the corticosteroid dose can be made as tolerated. The dose should be reduced gradually with medical supervision. In some patients, the dose of inhaled corticosteroids can be tapered off completely. Montelukast should not be abruptly substituted for inhaled corticosteroids.
Mode of administation: Oral.